Leukocytoclastic vasculitis associated with capecitabine.

IF 1 4区医学 Q4 ONCOLOGY

Journal of Oncology Pharmacy Practice Pub Date : 2024-10-01 Epub Date: 2023-04-06 DOI:10.1177/10781552231167812

Mustafa Ozgur Arici, Esin Avsar, Ozlem Kilic, Derya Kivrak Salim

{"title":"Leukocytoclastic vasculitis associated with capecitabine.","authors":"Mustafa Ozgur Arici, Esin Avsar, Ozlem Kilic, Derya Kivrak Salim","doi":"10.1177/10781552231167812","DOIUrl":null,"url":null,"abstract":"Background: Leukocytoclastic vasculitis (LCV) is a vasculitic inflammation against blood vessels. Various anticancer therapies can cause vasculitis, but capecitabine-induced LCV is an unusual entity. Here, we describe an LCV case associated with neoadjuvant capecitabine use for locally advanced rectal cancer (LARC).Case report: A 70-year-old man presented with rectal bleeding. A colonoscopic biopsy revealed rectal adenocarcinoma and he was diagnosed with LARC after imaging studies. Capecitabine plus radiation therapy was started as a neoadjuvant treatment.Management and outcome: Seven days after the first capecitabine dose, the patient was admitted with a rash. The LCV diagnosis was histopathologically proven. Capecitabine was withheld. After the patient's rash began to regress under corticosteroid pressure, capecitabine was started at a lower dose. His treatment was completed successfully with oral corticosteroids plus low-dose capecitabine.Discussion: We aimed to point out a rare and unusual adverse effect of a frequently used drug in oncologic practice.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1282-1286"},"PeriodicalIF":1.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oncology Pharmacy Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10781552231167812","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/6 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Leukocytoclastic vasculitis (LCV) is a vasculitic inflammation against blood vessels. Various anticancer therapies can cause vasculitis, but capecitabine-induced LCV is an unusual entity. Here, we describe an LCV case associated with neoadjuvant capecitabine use for locally advanced rectal cancer (LARC).

Case report: A 70-year-old man presented with rectal bleeding. A colonoscopic biopsy revealed rectal adenocarcinoma and he was diagnosed with LARC after imaging studies. Capecitabine plus radiation therapy was started as a neoadjuvant treatment.

Management and outcome: Seven days after the first capecitabine dose, the patient was admitted with a rash. The LCV diagnosis was histopathologically proven. Capecitabine was withheld. After the patient's rash began to regress under corticosteroid pressure, capecitabine was started at a lower dose. His treatment was completed successfully with oral corticosteroids plus low-dose capecitabine.

Discussion: We aimed to point out a rare and unusual adverse effect of a frequently used drug in oncologic practice.

查看原文本刊更多论文

与卡培他滨相关的白细胞胞浆性血管炎。

背景：白细胞凝集性血管炎（LCV）是一种血管炎。各种抗癌疗法均可引起血管炎，但卡培他滨诱发的 LCV 却并不常见。在此，我们描述了一例与局部晚期直肠癌（LARC）新辅助卡培他滨治疗相关的 LCV 病例：病例报告：一名 70 岁的男性出现直肠出血。结肠镜活检发现直肠腺癌，影像学检查后确诊为局部晚期直肠癌。作为新辅助治疗，他开始接受卡培他滨加放射治疗：首次服用卡培他滨七天后，患者因皮疹入院。组织病理学证实了LCV诊断。卡培他滨被暂停使用。在皮质类固醇的作用下，患者的皮疹开始消退，之后开始使用较低剂量的卡培他滨。通过口服皮质类固醇加小剂量卡培他滨，他的治疗顺利完成：讨论：我们的目的是指出在肿瘤治疗中一种常用药物的罕见和不寻常的不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Oncology Pharmacy Practice Medicine-Oncology

CiteScore

2.70

自引率

7.70%

发文量

276

期刊介绍： Journal of Oncology Pharmacy Practice is a peer-reviewed scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It is the official publication of the International Society for Oncology Pharmacy Practitioners (ISOPP). Publishing pertinent case reports and consensus guidelines...